Tradestie Institutional Equity Comparison Engine
APLS vs ZLAB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
APLS Overall Edge
APLS Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Apellis Pharmaceuticals, Inc. Common Stock (APLS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, APLS trades at 46.3x Forward P/E with 9.9% operating margin (+60.9% YoY revenue) versus ZLAB at N/M Forward P/E and -63.0% operating margin (-6.8% YoY). In options structure, APLS sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
APLS
APLS 46.3x vs ZLAB N/M Fwd P/E
Growth & Margin Winner
APLS
Op Margin 9.9% vs -63.0% ยท YoY +60.9% vs -6.8%
Momentum & Technical Winner
APLS
1Y +134.2% vs +9.7% ยท 52W Pos 100% vs 60%
Options & Structure Winner
APLS
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (58th %ile IV)
APLS
NASDAQ
Apellis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$41.03
-0.07% 1D
Market Cap
$5.3B
1M Return
+0.44%
1Y Return
+134.19%
Forward P/E
46.3x
Unified AI Score
60.2 / 100
BUY
Tech 40.0
Fund 52.0
Flow 67.0
Mom 50.0
ZLAB
NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap
$3.0B
1M Return
+2.76%
1Y Return
+9.66%
Forward P/E
N/M
Unified AI Score
47.4 / 100
HOLD
Tech 25.0
Fund 39.0
Flow 50.0
Mom 53.5
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
APLS +134.19%
ZLAB +9.66%
Spread: +112.92 pp (APLS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
APLS TTM Op. Margin: 9.9%
ZLAB TTM Op. Margin: -63.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on APLS vs ZLAB. Trailing 12-month operating profitability (APLS 9.9% vs ZLAB -63.0%) and valuation multiples (APLS 46.3x vs ZLAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | APLS | ZLAB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.3B | $3.0B | Larger Scale | APLS |
| Trailing P/E Ratio Valuation | 38.3x | N/M | Lower Multiple | APLS |
| Forward P/E Ratio Valuation | 46.3x | N/M | Lower Multiple | APLS |
| Revenue Growth (YoY) Growth | +60.9% | -6.8% | Higher Growth | APLS |
| Operating Margin (TTM) Profitability | 9.9% | -63.0% | Higher Margin | APLS |
| Net Profit Margin Profitability | 12.1% | -44.9% | Higher Margin | APLS |
| Return on Equity (ROE) Capital Efficiency | 46.0% | -30.0% | Higher ROE | APLS |
| 52-Week Range Position Momentum | 100% ($16โ$41) | 60% ($16โ$29) | Stronger Trend | APLS |
| Beta / 30D Volatility Risk Regime | 4.54ฮฒ ยท 2% Vol | 1.19ฮฒ ยท 78% Vol | Lower Realized Risk | APLS |
| Unified Institutional Score Composite Signal | 60.2 / 100 (BUY) | 47.4 / 100 (HOLD) | Higher Composite | APLS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full APLS vs ZLAB Buy Guide
APLS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
ZLAB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
58th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither APLS nor ZLAB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.